Dongfen Yuan

Dongfen Yuan

Auto-generated profile, based on publicly available information

Dongfen Yuan

Johnson & Johnson Spring House Pennsylvania USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
MKMyung Soo Kim
Myung Soo Kim
MHMatthew J. Haney
Matthew J. Haney
YZYuling Zhao
Yuling Zhao
DYDongfen Yuan
Dongfen Yuan
IDIrina Deygen
Irina Deygen
Elena BatrakovaElena Batrakova
Elena Batrakova

1 October 2017 in Biomaterials
Verified
Journal Article
Closed access
DYDongfen Yuan
Dongfen Yuan
YZYuling Zhao
Yuling Zhao
WBWilliam A. Banks
William A. Banks
KBKristin M. Bullock
Kristin M. Bullock
MHMatthew Haney
Matthew Haney
AKAlexander Kabanov
Alexander Kabanov

7 March 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
HHHua He
Hua He
DYDongfen Yuan
Dongfen Yuan
YWYun Wu
Yun Wu
YCyanguang cao
yanguang cao
Liposomal formulations have been developed to improve the therapeutic index of encapsulated drugs by altering the balance of on- and off-targeted distribution. The improved therapeutic efficacy of liposomal drugs is primarily attributed to enhanced distribution at the sites of action. The targeted distribution of liposomal drugs depends not only on the physicochemical properties of the liposomes, but also on multiple components of the biological system. Pharmacokinetic–pharmacodynamic (PK–PD) modeling has recently emerged as a useful tool with which to assess the impact of formulation- and system-specific factors on the targeted disposition and therapeutic efficacy of liposomal drugs. The use of PK–PD modeling to facilitate the development and regulatory reviews of generic versions of liposomal drugs recently drew the attention of the U.S. Food and Drug Administration. The present review summarizes the physiological factors that affect the targeted delivery of liposomal drugs, challenges that influence the development and regulation of liposomal drugs, and the application of PK–PD modeling and simulation systems to address these challenges.

19 July 2011 in Molecular Pharmaceutics
Verified
Journal Article
Closed access
ZSZhigui Su
Zhigui Su
JNJiangxiu Niu
Jiangxiu Niu
YXYanyu Xiao
Yanyu Xiao
QPQineng Ping
Qineng Ping
MSMinjie Sun
Minjie Sun
DYDongfen Yuan
Dongfen Yuan

15 September 2010 in Journal of Controlled Release
Verified
Journal Article
Closed access
YXYing Xu
Ying Xu
XJXuefeng Jin
Xuefeng Jin
QPQineng Ping
Qineng Ping
JCJuan Cheng
Juan Cheng
MSMinjie Sun
Minjie Sun
DYDongfen Yuan
Dongfen Yuan

1 October 2014 in Journal of Controlled Release
Verified
Journal Article
Closed access
XYXiang Yi
Xiang Yi
DYDongfen Yuan
Dongfen Yuan
SFSusan A. Farr
Susan A. Farr
WBWilliam A. Banks
William A. Banks
CPChi-Duen Poon
Chi-Duen Poon
AKAlexander Kabanov
Alexander Kabanov